Two abstracts reviewed venetoclax, the first FDA-approved BCL-2 inhibitor in acute myeloid leukemia (AML) and a novel BCL-2 inhibitor to treat chronic lymphocytic leukemia/small lymphocytic lymphoma ...

Researchers found that microplastics from everyday plastic tableware accumulate in human semen and, although not linked to ...

ROCKVILLE, Md. and SUZHOU, China, July 10, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in ...

Jennifer Brown, MD, PhD, Dana-Farber Cancer Institute, shared her thoughts on the current research regarding Bruton tyrosine kinase (BTK) and B-cell lymphoma 2 (BCL-2) inhibitors in chronic ...

Radioimmunoguided surgery after primary treatment of locally advanced breast cancer. The tumor-suppressor gene TP53 and the proto-oncogene bcl-2 encode, respectively, for a nuclear phosphoprotein and ...

Standout performers from Patrioti Levice, La Laguna Tenerife, MLP Academics Heidelberg, Galatasaray, and AEK Athens ...

Multimodal treatment of nodal localizations from Merkel cell carcinoma with no identifiable primary site and distant metastases. Background: Mebendazole (MBZ), a microtubule binding agent, is a potent ...

The second week of the 2025/26 Basketball Champions League regular season brought plenty of great games and interesting ...

While Eli Lilly celebrated a “solid quarter” of earnings this morning, a look over the Big Pharma’s third-quarter presentation reveals that the company has quietly dumped two clinical-stage assets.